213 related articles for article (PubMed ID: 34671949)
1. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 Jul; 12(7):1753-1773. PubMed ID: 34671949
[TBL] [Abstract][Full Text] [Related]
2. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 May; 12(5):1230-1252. PubMed ID: 34110597
[TBL] [Abstract][Full Text] [Related]
3. Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells.
Costa CP; Cunha S; Moreira JN; Silva R; Gil-Martins E; Silva V; Azevedo L; Peixoto AF; Sousa Lobo JM; Silva AC
Int J Pharm; 2021 Sep; 607():120933. PubMed ID: 34324988
[TBL] [Abstract][Full Text] [Related]
4. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
5. Anti-oxidant Containing Nanostructured Lipid Carriers of Ritonavir: Development, Optimization, and In Vitro and In Vivo Evaluations.
Jitta SR; Bhaskaran NA; Salwa ; Kumar L
AAPS PharmSciTech; 2022 Mar; 23(4):88. PubMed ID: 35296970
[TBL] [Abstract][Full Text] [Related]
6. Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters.
Cunha S; Costa CP; Loureiro JA; Alves J; Peixoto AF; Forbes B; Sousa Lobo JM; Silva AC
Pharmaceutics; 2020 Jun; 12(7):. PubMed ID: 32605177
[TBL] [Abstract][Full Text] [Related]
7. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
8. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, and
Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
[TBL] [Abstract][Full Text] [Related]
10. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
11. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.
Pant A; Sharma G; Saini S; Kaur G; Jain A; Thakur A; Singh B
Drug Deliv Transl Res; 2024 Mar; 14(3):730-756. PubMed ID: 37768530
[TBL] [Abstract][Full Text] [Related]
12. Enhanced tissue distribution of ritonavir-loaded nanostructured lipid carriers-recommending its dose reduction.
Jitta SR; Salwa ; Bhaskaran NA; Marques SM; Kumar L; Cheruku SP; Rao V; Sharma P; Kulkarni OP
Drug Deliv Transl Res; 2024 Jan; 14(1):116-130. PubMed ID: 37402943
[TBL] [Abstract][Full Text] [Related]
13. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations.
Mahmood A; Rapalli VK; Gorantla S; Waghule T; Singhvi G
Drug Deliv Transl Res; 2022 May; 12(5):1118-1135. PubMed ID: 33895936
[TBL] [Abstract][Full Text] [Related]
14. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method.
Kovács A; Berkó S; Csányi E; Csóka I
Eur J Pharm Sci; 2017 Mar; 99():246-257. PubMed ID: 28012940
[TBL] [Abstract][Full Text] [Related]
15. Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation.
Mainuddin ; Kumar A; Ratnesh RK; Singh J; Dumoga S; Sharma N; Jindal A
Med Oncol; 2024 Mar; 41(5):95. PubMed ID: 38526657
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Nanostructured Lipid Carriers of Fenofibrate Using a Box-Behnken Design for Oral Bioavailability Enhancement.
Wang H; Hong W; Li X; Jin Q; Ye W; Feng Y; Huang B; Tai Z; Chen L; Li Z; Wang Y; Yang Y; Gao C; Gong W; Yang M
Curr Drug Deliv; 2022; 19(7):773-787. PubMed ID: 33902411
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment.
Shekhawat P; Pokharkar V
Int J Pharm; 2019 Aug; 567():118415. PubMed ID: 31175989
[TBL] [Abstract][Full Text] [Related]
19. Quality-by-design based fabrication of febuxostat-loaded nanoemulsion: Statistical optimization, characterizations, permeability, and bioavailability studies.
Gurumukhi VC; Sonawane VP; Tapadiya GG; Bari SB; Surana SJ; Chalikwar SS
Heliyon; 2023 Apr; 9(4):e15404. PubMed ID: 37128342
[TBL] [Abstract][Full Text] [Related]
20. Topical nanostructured lipid carrier gel of quercetin and resveratrol: Formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer.
Imran M; Iqubal MK; Imtiyaz K; Saleem S; Mittal S; Rizvi MMA; Ali J; Baboota S
Int J Pharm; 2020 Sep; 587():119705. PubMed ID: 32738456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
